BTAI - BioXcel Therapeutics, Inc.
| Previous Close | 5.74 |
| Open | 5.72 |
| Bid | 5.66 x 1100 |
| Ask | 5.99 x 800 |
| Day's Range | 5.72 - 5.78 |
| 52 Week Range | 5.00 - 14.79 |
| Volume | 2,964 |
| Avg. Volume | 30,720 |
| Market Cap | 89.805M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.92 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 18.20 |
- GlobeNewswire•2 days ago
BioXcel Therapeutics Reports Positive Results from Study in Agitated Schizophrenia Patients Supporting BXCL501 Clinical Development
BioXcel Therapeutics, Inc. (“BTI”) (BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology, today announced positive results from a Phase 1b study evaluating intravenously (IV) administered dexmedetomidine (Dex) for acute treatment of agitation in patients suffering from schizophrenia. The trial met its primary endpoint by identifying a safe dose of IV Dex that produced a mild arousable sedation, defined by a RASS1 (Richmond Agitation Sedation Scale) score of -1.
- GlobeNewswire•7 days ago
BioXcel Therapeutics Reports Third Quarter 2018 Quarterly Results and Provides Business Update
NEW HAVEN, Conn., Nov. 09, 2018 -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial.
- GlobeNewswire•11 days ago
BioXcel Therapeutics Announces FDA Acceptance of IND for Lead Immuno-oncology Candidate, BXCL701, in Treatment Emergent Neuroendocrine Prostate Cancer
BioXcel Therapeutics, Inc. (“BTI” or “Company”) (BTAI), today announced that the U.S. Food and Drug Administration (“FDA”), has accepted its Investigational New Drug (“IND”) application for its lead immuno-oncology candidate, BXCL701. BTI plans to evaluate BXCL701 in combination with pembrolizumab (Keytruda®) as a potential therapy for treatment-emergent neuroendocrine prostate cancer (“tNEPC”), with the trial expected to initiate in the fourth quarter of 2018.
- GlobeNewswire•14 days ago
BioXcel Therapeutics to Host Third Quarter 2018 Financial Results and Business Update Conference Call
Conference call scheduled for November 09, 2018 at 8:00 AM ET NEW HAVEN, Conn., Nov. 02, 2018 -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage.
- GlobeNewswire•16 days ago
BioXcel Therapeutics Announces Presentation on Functional Immunological Memory Formation Across Diverse Tumor Types at the SITC 2018 Annual Meeting
Data underscores the potential of triple combination of BXCL701, NKTR-214 and an anti-PD1 agent as an anti-cancer therapy NEW HAVEN, Conn., Oct. 31, 2018 -- BioXcel.
- GlobeNewswire•17 days ago
BioXcel Therapeutics Provides Update on the Clinical Advancement of BXCL501 for the Acute Treatment of Agitation
BioXcel Therapeutics, Inc. (“BTI”) (BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify the next wave of medicines across neuroscience and immuno-oncology, today provided an update on the Company’s progress advancing its lead neuroscience program, BXCL501, a proprietary, first-in-class sublingual thin film formulation of dexmedetomidine hydrochloride (“Dex”) being developed for the acute treatment of agitation. BTI is on track to initiate an IND-opening Phase 1 pharmacokinetic (“PK”) and safety study with BXCL501 by the end of this year, following approval of its IND application.
- GlobeNewswire•last month
BioXcel Therapeutics to Present at the 2018 BIO Investor Forum
NEW HAVEN, Conn., Oct. 11, 2018 -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial.
- GlobeNewswire•last month
BioXcel Therapeutics Announces Submission of IND for Lead Immuno-oncology Candidate, BXCL701, in Treatment Emergent Neuroendocrine Prostate Cancer
BioXcel Therapeutics, Inc. (“BTI”) (BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify the next wave of medicines across neuroscience and immuno-oncology, today announced it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (“FDA”) to evaluate its lead immuno-oncology candidate, BXCL701, in combination with pembrolizumab (Keytruda®) as a potential therapy for treatment emergent neuroendocrine prostate cancer (“tNEPC”). BTI expects to initiate the trial, subject to IND approval, in the fourth quarter of 2018.
- GlobeNewswire•2 months ago
BioXcel Therapeutics Expands Immuno-Oncology Partnership with Nektar into Clinical Development in Pancreatic Cancer
BioXcel Therapeutics, Inc. (“BTI”) (BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify the next wave of medicines across neuroscience and immuno-oncology, and Nektar Therapeutics (NKTR) announced today that the companies are expanding their ongoing research collaboration into a new clinical partnership.
- GlobeNewswire•2 months ago
BioXcel Therapeutics Enhances Leadership with Appointment of Chetan D. Lathia, Ph.D. as Senior Vice President, and Head of Translational Medicine, Clinical Pharmacology and Regulatory Affairs
Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, commented, “Over the last several months, we have developed our corporate infrastructure through a number of key strategic hires, and we are pleased that Dr. Lathia has joined BTI.
- GlobeNewswire•2 months ago
BioXcel Therapeutics Appoints Dr. David C. Hanley as Vice President and Head of Global Pharmaceutical Development and Operations
BioXcel Therapeutics, Inc. (“BTI”) (BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology, today announced the appointment of Dr. David C. Hanley as Vice President and Head of Global Pharmaceutical Development and Operations, effectively immediately. Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, commented, “David possesses a wealth of knowledge and expertise in drug development, clinical and commercial manufacturing, and supply chain management which will be instrumental in the success of our clinical programs, BXCL501 and BXCL701, as well as setting the stage for our commercial operations.
- GlobeNewswire•3 months ago
BioXcel Therapeutics to Present at the 20th Annual HC Wainwright Global Investment Conference
NEW HAVEN, Conn., Aug. 28, 2018-- BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify the next wave of medicines ...
- GlobeNewswire•3 months ago
BioXcel Therapeutics Establishes Immuno-Oncology Clinical Advisory Board to Advance BXCL701 Development
BioXcel Therapeutics, Inc. (“BTI”) (BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify the next wave of medicines across neuroscience and immuno-oncology, today announced the formation of an immuno-oncology clinical advisory board (CAB). The newly formed CAB will play an integral role in the development of BXCL701, a first-in-class DPP8/9 and FAP inhibitor, currently being developed for the treatment of pancreatic and treatment emergent neuroendocrine prostate cancer (tNEPC). The CAB will also support BTI’s future immuno-oncology candidates identified through the Company’s artificial intelligence (AI) innovation lab partnership with BioXcel Corporation.
- ACCESSWIRE•3 months ago
BioXcel Therapeutics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 8, 2018 / BioXcel Therapeutics, Inc. (NASDAQ: BTAI ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 4:30:00 PM Eastern ...
- InvestorPlace•4 months ago
7 Best Stocks to Buy to Upgrade Your AI Portfolio
Precious few other industries will lever an indelible impact quite like artificial intelligence. From an investment perspective, AI companies represent some of the best stocks to buy. As MIT Sloan Management Review explains, “Virtually all human achievements have been made by groups of people, not lone individuals.” In other words, innovation, according to the brilliant minds at MIT, is inherently collaborative.
- InvestorPlace•4 months ago
7 Megatrend Stocks With Long-Term Upside Potential
For instance, driver assistance systems, such as those developed by Nvidia Corporation (NASDAQ:NVDA), rightfully falls under this category. Another innovation is the rapidly-growing Internet of Things (IoT) concept, which describes the internet connectivity of everyday devices. Here are seven megatrend stocks with massive, long-term potential.
